此外，多瑞医药在营收上高度依赖一款大单品醋酸钠林格注射液，但该产品近年来由于集采、陆续从各 地方医保目录中调出等原因，销售收入下滑显著，进而拖累了公司业绩。 三家上市公司同日宣布停牌筹划控制权变更。 9月28日晚间，多瑞医药（301075）(SZ301075，前收盘价40.08元，市值32.06亿元)、亚太药业 （002370）(SZ002370，前收盘价5.67元，市值42.28亿元)、中环环保（300692）(SZ300692，前收盘价 8.86元，市值37.61亿元)三家A股上市公司发布公告，其各自的控股股东正在筹划上市公司控制权变更 相关事宜，该事项可能导致公司控股股东、实际控制人发生变更。 公告显示，9月29日(星期一)开市起，上述三家上市公司的股票停牌，预计停牌时间均不超过两个交易 日。此外，三家公司的公告均提示风险称，上述控制权变更事项尚在筹划中，存在不确定性。 《每日经济新闻》记者了解到，上述三家上市公司中，多瑞医药、亚太药业为医药企业。其中，多瑞医 药主要从事血浆代用品的生产、销售，亚太药业则是一家传统仿制药企业。财报显示，上述两家药企的 业绩已连续下滑多年，这或是控股股东筹划将其"易手"的 ...

Core Viewpoint - The exit of Weizhi Energy marks a significant turning point for Yijing Photovoltaic, transitioning the company into a "no owner" status after a judicial transfer of shares, leading to a change in actual control [1][10]. Group 1: Share Transfer and Control Change - Weizhi Energy's shares, approximately 150 million, were publicly auctioned by the Futian Court, resulting in a reduction of its holdings from 12.67% to 8.45% [1][2]. - The shares were divided into three batches, each sold to different buyers at prices around 3.05 to 3.08 yuan per share, totaling approximately 1.5 million yuan for each batch [2][3]. - The auction and subsequent transfer of shares signify a forced exit for Weizhi Energy due to financial pressures from its associated real estate company [4]. Group 2: Financial Performance and Challenges - Yijing Photovoltaic experienced significant financial struggles, with a debt ratio nearing 95% and a history of substantial losses since 2012, exacerbated by industry downturns and operational challenges [4][11]. - In 2022, the company reported a revenue of 9.876 billion yuan and a net profit of approximately 127 million yuan, but faced a sharp decline in 2023, with revenue and net profit both decreasing [5][7]. - Projections for 2024 indicate a revenue drop of 57.07% and a loss of approximately 2.09 billion yuan, with no profitable quarters anticipated [6][7]. Group 3: Governance and Future Outlook - The absence of a controlling shareholder raises governance concerns, as decision-making will rely on board collaboration, which could lead to inefficiencies [8][10]. - The company is under scrutiny from the Shanghai Stock Exchange regarding the potential risks associated with having no actual controller and the implications for corporate governance [9][10]. - Despite the challenges, the removal of Weizhi Energy may provide Yijing Photovoltaic an opportunity to shed historical burdens and potentially improve its operational strategies moving forward [8][12].

中达安（300635）9月发布关于公司申请向特定对象发行股票的审核问询函之回复，拟向厦门建熙兴成 科技合伙企业（有限合伙）发行股票不超过42,040,200股，募集资金不超过3.66亿元，扣除发行费用后 全部用于补充流动资金及偿还债务。发行完成后，公司控股股东将由济南历控帝森股权投资合伙企业 （有限合伙）变更为厦门建熙，实际控制人将由济南市历城区财政局变更为王立。 信立集团旗下新能源业务与发行人业务在业务、场景及资本层面具有协同效应，取得控制权将助力上市 公司业务转型和盈利能力提升。王立具有丰富的企业管理、投资及产业运营经验，控制的信立集团形成 了投资、实业双轮驱动布局，具备实际控制和经营管理上市公司的能力。发行完成后，厦门建熙将依法 行使股东权利调整董事会和管理团队，公司管理团队整体保持稳定，保障生产经营稳定。 历城区财政局放弃控制权原因 历城控股面临业务转型，且希望引进智能制造项目发展地方主导产业。信立集团产业方向与济南市及历 城区重点发展产业重合，其下属公司拟在济南设立子公司并投资建设生产基地。因此，历城区财政局放 弃控制权具有合理性。 前次再融资撤回影响 厦门建熙情况及资金来源 厦门建熙设立于2024 ...

Core Viewpoint - The actual controller of Tianyu Biological has changed from a dual control by Luo Weiguo and Shi Dongwei to a single control by Luo Weiguo, following the signing of a termination agreement on August 25, 2025 [1][2] Group 1: Changes in Management and Control - Shi Dongwei has resigned as the president of the company to support Luo Weiguo in managing the company, while continuing to serve as the vice chairman of the board [2] - Shi Dongwei has signed a commitment not to seek control over Tianyu Biological and will not interfere with Luo Weiguo's control [2][3] - After the termination of the joint action relationship, Luo Weiguo holds 37.25 million shares, representing 12.84% of the voting rights [2] Group 2: Fundraising and Share Issuance - The company plans to issue shares to raise no more than 465 million yuan, with the funds used for working capital and debt repayment [2] - The share issuance will increase Luo Weiguo's direct and indirect control of the company from 12.84% to 29.98%, stabilizing his control [3] Group 3: Business Performance and Financial Health - Tianyu Biological has faced continuous losses over the past five years, with net profits of -157 million yuan, -215 million yuan, -312 million yuan, -462 million yuan, and -107 million yuan from 2020 to 2024 [3] - The company's debt ratio has remained high, reaching 75.91% as of the end of the first quarter of 2025 [3]

Core Points - The controlling shareholder and actual controller of Kehua Holdings Co., Ltd. will change from Chen Hongmin and Chen Xiaoke to Lu Hongping and Tu Han [1][2] - The change will occur through a series of share transfer agreements, with the first phase involving the transfer of 31,454,679 shares [2][3] - Following the completion of the first phase, the acquirers will hold 19.64% of the shares, and their voting rights will be adjusted accordingly [3][7] - A second phase of share transfer is planned, with a total of 9,766,073 shares to be acquired by the new controllers [2][8] - The company plans to issue 30,000,000 A-shares, with the acquirers intending to fully subscribe to this issuance [4][9] - After the issuance, the acquirers' shareholding will increase to 34.73%, while the original controllers' shareholding will decrease to 11.16% [9][10] Share Transfer Details - The first phase of the share transfer involves a total payment of approximately 517.74 million yuan for the shares [14][24] - The share transfer price is set at 16.46 yuan per share, with the total transfer price for the first phase being 293,747,464.40 yuan [16][26] - The second phase of the share transfer is expected to be completed by March 31, 2026, with specific agreements to be signed by January 10, 2026 [2][8] Corporate Governance Changes - Post-transfer, the new controllers will have the right to nominate four non-independent directors and several vice presidents [3][7] - The original controllers will retain the right to nominate two non-independent directors, ensuring a balance in governance [7][8] Financial Implications - The total expected fundraising from the share issuance is approximately 326.1 million yuan, aimed at improving the company's liquidity [9][10] - The funds raised will be used to enhance the company's working capital and improve its financial structure [10][11]

Core Viewpoint - Yonghe Intelligent Control announced the termination of the control change, which was previously disclosed on August 6, leading to a significant stock price fluctuation [2][4]. Group 1: Control Change Announcement - On August 12, Yonghe Intelligent Control received a notice from its controlling shareholder, Cao Delin, indicating the termination of the share transfer agreement signed on August 5, 2025, with Hangzhou Runfeng Intelligent Equipment Co., Ltd. [2][6]. - The share transfer involved 35.66 million shares (8% of total shares) at a price of 8.9736 yuan per share, totaling 320 million yuan [6][7]. Group 2: Stock Price Reaction - Following the announcement of the control change on August 6, the stock price of Yonghe Intelligent Control hit the daily limit up on August 5, but dropped sharply by 5.8% on August 6 after opening high [4][7]. - The stock experienced a continuous decline over the next five trading days, with a cumulative drop of 15% [12]. Group 3: Reasons for Termination - The termination was due to Hangzhou Runfeng's failure to pay the first installment of the share transfer payment of 20 million yuan by the agreed deadline [9][10]. - The agreement stipulated that if the payment was not made within the specified time, the transfer agreement would be deemed invalid and automatically terminated [9][10]. Group 4: Company Financial Performance - Yonghe Intelligent Control's main business focuses on the production and operation of household water heating valves and fittings, contributing approximately 85% to revenue, while tumor precision radiation therapy contributes less than 15% [14]. - The company has been experiencing continuous losses over the past three years, with a projected net profit loss of 294 million yuan for 2024 [14][15].

Core Viewpoint - Yonghe Intelligent Control announced the termination of a control change transaction involving its major shareholder, Cao Delin, due to non-payment by Hangzhou Runfeng Intelligent Equipment Co., Ltd. [1][5] Group 1: Control Change Announcement - On August 6, Yonghe Intelligent Control disclosed a control change plan, which led to a stock price surge and subsequent drop, closing down 5.8% on the same day [2][4] - The control change involved the transfer of 35.66 million shares (8% of total shares) from Cao Delin to Hangzhou Runfeng at a price of 8.9736 yuan per share, totaling 320 million yuan [3][4] Group 2: Payment Issues - The transaction was terminated because Hangzhou Runfeng failed to pay the initial transfer amount of 20 million yuan by the agreed deadline [5][6] - The agreement stipulated that if the payment was not made within the specified timeframe, the transfer agreement would be deemed invalid and automatically terminated [5][6] Group 3: Market Reaction and Financial Performance - Following the announcement of the control change, Yonghe Intelligent Control's stock experienced a significant decline, with a cumulative drop of 15% over five trading days [7] - The company has been facing continuous losses, with a projected net loss of 294 million yuan for 2024, primarily from its main business in household plumbing valves and fittings [7]

Group 1 - The core point of the article is the change of control in *ST Huazhong, where the actual controller will shift from Lou Yongliang to Lin Muxun, leading to a significant market reaction with the stock hitting the daily limit on August 12 [1][3][5] - The stock price of *ST Huazhong closed at 6.74 yuan per share on August 12, with a total market capitalization of approximately 1.318 billion yuan [3] - The transaction involves Zhejiang Hengshun and Shanghai Tianji transferring a total of approximately 48.9 million shares, representing 25.01% of the company's total shares, to Hainan Bocheng Huineng Technology Center for about 450 million yuan [3][4] Group 2 - *ST Huazhong has reported continuous losses over the past four years, with net profits of approximately -8.86 million yuan, -6.49 million yuan, -8.28 million yuan, and -4.68 million yuan from 2021 to 2024 [7] - The company’s revenue has also been declining, with figures of approximately 130 million yuan, 125 million yuan, 122 million yuan, and 117 million yuan for the same years [7] - The first quarter of 2025 showed a revenue of approximately 2.0045 million yuan, a year-on-year decrease of 8.78%, and a net profit of approximately -103.61 million yuan [7][8] Group 3 - The new controlling entity, Bocheng Huineng, was established specifically for this acquisition, with a registered capital of 24 million yuan, of which only 2 million yuan has been paid in as of the announcement date [5][6] - The Shanghai Stock Exchange has raised concerns regarding the financial capabilities of Bocheng Huineng and its partners, questioning the sources of funds for the acquisition and their ability to fulfill the transaction [5][6] - The market generally anticipates positive changes when a capable acquirer takes control of a listed company, which can lead to improved fundamentals and stock performance [4]

Core Viewpoint - The announcement by Qidi Pharmaceutical indicates a significant change in its shareholding structure, with Hunan Sailuxian acquiring a substantial stake, leading to a shift in control of the company [1][2]. Group 1: Shareholding Changes - Qidi Pharmaceutical announced that Hunan Sailuxian will acquire 58.607 million shares from Qidi Technology Service Co., resulting in a decrease of Qidi Technology's holdings from 63.151 million shares to 4.544 million shares, reducing its ownership percentage from 26.37% to 1.90% [1][3]. - Following this transaction, Hunan Sailuxian will hold 24.47% of Qidi Pharmaceutical's shares, making it the largest shareholder, surpassing Qidi Technology Service [2][5]. Group 2: Financial Details - The shares were sold at an average price of 17.19 yuan per share, totaling approximately 1.007 billion yuan for the transaction [5]. - As of August 8, Qidi Pharmaceutical's market capitalization was approximately 2.85 billion yuan, with a closing price of 11.90 yuan per share [6]. Group 3: Company Background - Qidi Pharmaceutical, established in 1956, is recognized as Hunan Province's first pharmaceutical listed company and has notable brands such as "Guhan" [5].

Core Viewpoint - The auction of shares held by Zheng Suzhen, mother of Xu Xiang, in Daheng Technology (600288) has attracted significant market attention, with the shares sold at a premium price compared to the initial listing price [3][4]. Summary by Sections - The judicial auction of 130 million shares (29.75% ownership) of Daheng Technology was completed after 501 bids, with a final transaction price of 1.712 billion yuan, representing a 60.29% premium over the starting price of 1.068 billion yuan [4]. - Li Rongrong emerged as the largest winner in the auction, acquiring 27.46 million shares, which is 21.13% of the auctioned shares, at a price of 13.17 yuan per share, totaling 362 million yuan. Following this transaction, she holds 6.29% of Daheng Technology, becoming the largest single shareholder [5]. - Li Rongrong, born in 1975 and residing in Ningbo, has been a mid-level manager at Ningbo Jinhai Logistics Service Co., Ltd. since 2018. The company is a wholly-owned subsidiary of the Ningbo Customs Logistics Management Center [6]. - Li Rongrong stated that her investment in Daheng Technology is based on a long-term recognition of the company's value and future prospects, with no plans for shareholding changes or significant adjustments to the company's main business in the next 12 months. The funds for her share acquisition were sourced from her own or self-raised funds, which were paid on July 28 [7]. - Other investors also invested significantly in the auction, with China New Era Co., Ltd. spending 237 million yuan for 18 million shares, while other investors like Wang Xiaoping and Yang Runzhong each spent around 237 million yuan [8]. - The auction will significantly impact the shareholding structure of Daheng Technology. If the transfer of shares is completed, Zheng Suzhen will no longer hold any shares, leading to a change in control of the company. However, the company asserts that its operations remain normal and that the change in control will not adversely affect its governance structure or operations [9].